Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
A number of other equities research analysts have also weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Finally, Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a research report on Friday, October 16th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.18.
Check Out Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Price Performance
Shares of RXRX stock opened at $3.52 on Friday. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $5.24. The stock’s fifty day moving average price is $3.77 and its 200 day moving average price is $3.52. The company has a market cap of $2.19 billion, a price-to-earnings ratio of -3.91 and a beta of 1.15.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative return on equity of 47.85% and a negative net margin of 697.15%. The company had revenue of $18.55 million for the quarter, compared to analyst estimates of $14.81 million. During the same period in the prior year, the company posted ($0.36) EPS. As a group, equities research analysts anticipate that Recursion Pharmaceuticals will post -0.89 earnings per share for the current year.
Insider Buying and Selling
In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. The trade was a 1.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the transaction, the director directly owned 162,156 shares in the company, valued at $810,780. This represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 167,408 shares of company stock worth $701,276 in the last 90 days. Insiders own 6.65% of the company’s stock.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Ascent Wealth Partners LLC increased its stake in shares of Recursion Pharmaceuticals by 11.8% in the 1st quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock valued at $86,000 after purchasing an additional 2,974 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Recursion Pharmaceuticals by 33.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company’s stock worth $52,000 after purchasing an additional 4,199 shares during the period. Sequoia Financial Advisors LLC boosted its position in Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after purchasing an additional 5,156 shares in the last quarter. MCF Advisors LLC purchased a new position in Recursion Pharmaceuticals during the second quarter worth approximately $27,000. Finally, Jacobi Capital Management LLC purchased a new position in Recursion Pharmaceuticals during the third quarter worth approximately $31,000. Institutional investors and hedge funds own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.
Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
